Halozyme Therapeutics (NASDAQ:HALO) Analyst Rating Consensus

Halozyme Therapeutics (NASDAQ:HALO) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.6 by 5 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys. A sell rating was given by 1 analyst.

Other Equity analysts have also commented on the company shares. In the latest statement by the brokerage house, JMP Securities maintains its outlook on Halozyme Therapeutics (NASDAQ:HALO). The current rating of the shares is Market Outperform, according to the research report released by the firm. The brokerage firm lowers the price target from $22 per share to $20 per share. The rating by the firm was issued on March 9, 2016.

Halozyme Therapeutics (NASDAQ:HALO) should head towards $12.58 per share according to 3 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $7 per share. The higher price estimate target is at $16 according to the Analysts.

Halozyme Therapeutics (NASDAQ:HALO) witnessed a decline in the market cap on Tuesday as its shares dropped 1.09% or 0.095 points. After the session commenced at $8.71, the stock reached the higher end at $8.71 while it hit a low of $8.4175. With the volume soaring to 1,254,064 shares, the last trade was called at $8.6. The company has a 52-week high of $25.25. The company has a market cap of $1,111 million and there are 129,139,743 shares in outstanding. The 52-week low of the share price is $6.96.

Halozyme Therapeutics, Inc. has lost 3.15% in the last five trading days and dropped 6.01% in the last 4 weeks. Halozyme Therapeutics, Inc. has dropped 7.63% during the last 3-month period . Year-to-Date the stock performance stands at -50.38%.

Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.